Scheduled infliximab monotherapy to prevent recurrence of Crohnʼs disease following ileocolic or ileal resection: A 3-year prospective randomized open trial

Infliximab Therapy Impacts the Peripheral Immune System of Immunomodulator and Corticosteroid Naive Patients with Crohn' Disease

(2011) Kyoichi Kato et al.   Gut and Liver

5-Aminosalicylates Prevent Relapse of Crohn's Disease After Surgically Induced Remission: Systematic Review and Meta-Analysis

(2010) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?

(2010) Gionata Fiorino et al.   CURRENT DRUG TARGETS

Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial

(2010) W. Reinisch et al.   GUT

Validating Crohnʼs disease activity indices for use in assessing postoperative recurrence

(2010) T. D. Walters et al.   INFLAMMATORY BOWEL DISEASES

What is the optimal therapy for Crohn’s disease: step-up or top-down?

(2010) Ming Valerie Lin et al.   Expert Review of Gastroenterology & Hepatology

Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn’s disease

(2009) Takayuki Yamamoto et al.   JOURNAL OF GASTROENTEROLOGY

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

(2008) Miguel Regueiro et al.   GASTROENTEROLOGY

Impact of azathioprine on the prevention of postoperative Crohnʼs disease recurrence: Results of a prospective, observational, long-term follow-up study

(2008) Eugeni Domènech et al.   INFLAMMATORY BOWEL DISEASES